Prognostic factors and molecular markers for renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 1, Issue 4, 2001, Pages 565-575

  Bui, Matthew H ^a   Zisman, Amnon ^a   Pantuck, Allan J ^a   Han, Ken Ryu ^a   Wieder, Jeff ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Classification; Genetics; Kidney; Molecular markets; Prognostic factors; Renal cell; Staging

Indexed keywords

ALPHA INTERFERON; CARBONATE DEHYDRATASE; CELL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; GLYCOPROTEIN; INTERLEUKIN 2; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR MARKER; UVOMORULIN; VASCULOTROPIN;

ADVANCED CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REVIEW; UNITED STATES;

EID: 0035559915     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.4.565     Document Type: Review

References (97)

1. Current prognostic factors-renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)
2. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)
3. Cystic renal cell carcinoma: Pathological features, survival and implications for treatment
4. Subtypes of renal cell carcinoma. Different onset and sites of metastatic disease
5. Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases
6. Chromophobe cell renal carcinoma: Clinicopathological features of 50 cases
7. Papillary renal cell carcinoma: Clinicopathological characteristics and evaluation of prognosis in 42 patients
8. Collecting duct carcinoma of the kidney
9. Collecting duct renal cell carcinoma: Clinical study of a rare tumor
10. Renal medullary carcinoma. The seventh sickle cell nephropathy
11. Renal medullary carcinoma: Clinical and therapeutic aspects of a newly described tumor
12. Prognostic significance of morphologic parameters in renal cell carcinoma
13. Prognostic factors in renal cancer
14. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases
15. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases
16. Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 tumor, nodes and metastases staging criteria
17. Sarcomatoid renal carcinoma
18. Sarcomatoid renal cell carcinoma. A treatable entity
19. Sarcomatoid renal cell carcinoma. A study of its proliferative activity
20. Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. I
21. Sarcomatoid renal cell carcinoma: Clinicopathologic. A study of 42 cases
22. Stratification of risk factors in renal cell carcinoma
23. The results of radical nephrectomy for renal cell carcinoma
24. Tumor, nodes and metastases classification of malignant tumors, fifth edition Union Internationale Contre le Cancer and the American Joint Committee on Cancer
25. Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival
26. Renal cell carcinoma extending into the inferior vena cava: The prognostic significance of the level of vena caval involvement
27. Prognostic implications of vena caval extension of renal cell carcinoma
28. Surgical management and prognosis of renal cell carcinoma invading the vena cava
29. Improved prognostication of renal cell carcinoma using an integrated staging system
30. Impact of tumor size on the clinical outcomes of patients with Robson Stage I renal cell carcinoma
31. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year follow-up
32. Nephron sparing surgery for localized renal cell carcinoma: Impact of tumor size on patient survival, tumor recurrence and tumor, nodes and metastases staging
33. Re-evaluation of the 1997 tumor, nodes and metastases classification for renal cell carcinoma: T1 and T2 cut-off point at 4.5 rather than 7 cm better correlates with clinical outcome
34. Stage pT1 conventional (clear cell) renal cell carcinmoa: Pathological features associated with cancer specific survival
35. Pathologic staging of renal cell carcinoma: Significance of tumor classification with the 1997 tumor, nodes and metastases staging system
36. Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes and metastases stage 1 and stage 2 patients
37. Stage I renal cell carcinoma. A clinicopathologic study of 82 cases
38. A postoperative prognostic nomogram for renal cell carcinoma
39. Evaluation of the 1997 tumour, nodes and metastases classification of renal cell carcinoma: Experience in 172 patients
40. Increased incidental detection and reduced mortality in renal cancer-recent retrospective analysis at eight institutions
41. Renal cell carcinoma as an incidental finding
42. Improvement in survival of patients with renal cell carcinoma-the role of the serendipitously detected tumor
43. Renal cell carcinoma: Incidental diagnosis and natural history: Review of 235 cases
44. Increased incidence of serendipitously discovered renal cell carcinoma
45. Renal cell carcinoma: Prognostic significance of incidentally detected tumors
46. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma
47. Prognostic factors in metastatic renal carcinoma
48. The natural history of metastatic renal cell carcinoma: A computer analysis
49. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma
50. Prognostic factors in renal cell carcinoma renal cell carcinoma: Immunotherapy and cellular biology
51. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
52. Surgical removal of pulmonary metastases from renal cell carcinoma
53. Cytoreductive nephrectomy in metastatic renal cell carcinoma: The result of Southwest Oncology Group (SWOG) trial 8949
54. EORCTC-GU group: Tumor nephrectomy plus interferon-α is superior to interferon-α alone in metastatic renal cell carcinoma
55. Renal tumors
56. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma
57. Risk and prognosis in renal neoplasms. A pathologist's prospective
58. Clinicopathologic study of 97 cases of small renal cell carcinomas using DNA flow cytometric analyses
59. Collecting duct carcinoma of kidney
60. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma
61. Prognostic relevance of AgNORs in tumor pathology
62. Renal cell carcinoma: Current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)
63. Nucleolar organizer regions and prognosis in renal cell carcinoma
64. Prognostic value of ploidy and proliferation markers in renal cell carcinoma
65. Histopathologic prognostic indicators for renal cell carcinoma
66. Prognostic factors of renal cell carcinoma: A multivariate analysis
67. Comparative study of the prognostic value of nuclear grade and silver-binding nucleolar organizer region in renal cell carcinomas
68. Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas. A clinicopathologic study of 58 patients using mitotic count, MIB-1 staining and DNA cytophotometry
69. Clinical outcome in localized renal cell carcinomas related to immunoexpression of proliferating cell nuclear antigen, Ki-67 antigen and tumor size
70. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma
71. Prognostic value of Ki-67 expression in renal cell carcinomas
72. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma
73. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma
74. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma
75. CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma
76. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma
77. Prognostic factors in renal-cell carcinoma: Immunohistochemical detection of p53 protein versus clinico-pathological parameters
78. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: No evidence for prognostic significance
79. Expression of bcl-2, p53 oncoprotein and proliferating cell nuclear antigen in renal cell carcinoma
80. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas
81. Expression of bcl-2 oncoprotein in renal cell tumours
82. Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma
83. P53, bcl-2 and Bax expression in renal cell carcinoma
84. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival
85. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma
86. Decreased expression of α-catenin is associated with poor prognosis of patients with localized renal cell carcinoma
87. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships
88. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney
89. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma
90. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
91. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma
92. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma
93. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro
94. The expression of G250/mn/CA9 antigen by flow cytometry: Its possible implication for detection of micrometastatic renal cancer cells
95. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
96. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
97. Microvessel density in renal cell carcinoma: Lack of prognostic significance